BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01870505
First received: June 3, 2013
Last updated: March 16, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: May 2016
  Estimated Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)